drugset / Trial / NCT01193855

Dutasteride in Treating Patients With Prostate Cancer

NCT01193855

Phase 2 Unknown 42 enrolled University College London Hospitals
RandomizedDouble-blindTreatment

Summary

RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well giving dutasteride works in treating patients with prostate cancer.

Timeline

Start
2010-06
Primary completion
2012-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutasteride Small molecule 0.5 mg Oral

Indications